What Is Claimed Is:

CLAIMS

1. An antibody or antigen-binding portion thereof, wherein said antibody or antigen-binding portion thereof specifically binds to an E-protein, Domain II (E-DII) epitope of a Yellow Fever (YF) Virus, ~~and~~ wherein the E-DII epitope comprises the amino acids at positions 93, 104 and 106 of~~an asparagine at position 106, a lysine at position 93, and a lysine at position 104 of~~ the ~~Yellow Fever Virus E protein~~YF E-DII, which positions correspond to those of the 17D YF vaccine strain.

2. The antibody or antigen-binding portion thereof of claim 1, wherein the antibody or antigen-binding portion thereof comprises three CDRs of a heavy chain variable region (VH), wherein the VH comprises an amino acid sequence selected from the group consisting of SEQ ID. NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, and 36~~.~~

~~3. The antibody or antigen-binding portion thereof of claim 1 or 2~~, and wherein the antibody or antigen-binding portion thereof comprises three CDRs of a light chain variable region (VL), wherein the VL comprises an amino acid sequence selected from the group consisting of SEQ ID. NOs: 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, and 73.

34. The antibody or antigen-binding portion thereof ~~of any one of the preceding claims~~claim 1 or 2, wherein the antibody or antigen-binding portion thereof comprises a VH, wherein the VH comprises an amino acid sequence selected from the group consisting of SEQ ID. NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, and 36~~.~~

~~5. The antibody or antigen-binding portion thereof of any of claims 1-4~~, and wherein the antibody or antigen-binding portion thereof comprises a VL, wherein the VL comprises an amino acid sequence selected from the group consisting of SEQ ID. NOs: 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, and 73.

46. The antibody or antigen-binding portion thereof of any of the preceding claims, wherein the antibody or antigen-binding portion thereof is a human antibody or antigen-binding portion thereof, a monoclonal antibody or antigen-binding portion thereof, a chimeric antibody or antigen-binding portion thereof, or a humanized antibody or antigen-binding portion thereof.

57. The antibody or antigen-binding portion thereof of any of the preceding claims, wherein the antibody or antigen-binding portion thereof is a single chain antibody or antigen-binding portion thereof, a F(ab') 2 fragment, a dAb fragment, a Fab fragment, or a Fv fragment.

68. The antibody or antigen-binding portion thereof of any of the preceding claims, wherein the antibody or antigen-binding portion thereof is an isolated antibody or antigen-binding portion thereof.

79. A composition comprising an antibody or antigen-binding portion thereof of any of the preceding claims and a carrier.

810. The composition of claim 79, wherein the composition is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier.

911. An antibody or antigen-binding portion thereof for use in medicament, wherein the antibody or antigen-binding portion thereof is any of claims 1-68.

102. Use of the antibody or antigen-binding portion thereof of any of claims 1-68 in the manufacture of a medicament for treating a disease or condition associated with Yellow Fever Virus.

113. A nucleic acid comprising a nucleotide sequence encoding an antibody heavy chain variable region (VH), an antibody light chain variable region (VL) or both, wherein the VH and VL is set forth in ~~any of claims 2-7~~claim 2 or 3.

124. A vector comprising the nucleic acid of claim 113.

135. The vector of claim 124, wherein the vector is an expression vector.

146. A host cell comprising the nucleic acid of claim 113 or the vector of ~~claims 14 or 15~~claim 12 or 13.

157. A method for producing an antibody or antigen-binding portion thereof ~~that binds to Yellow Fever Virus E protein~~, comprising:

culturing the host cell of claim 146 under conditions allowing for expression of the antibody.

168. The method of claim 157, further comprising harvesting the antibody or antigen-binding portion thereof.

~~19. The method of claim 17 or 18, wherein the antibody or antigen-binding portion thereof specifically binds to the E-DII epitope of Yellow Fever Virus E protein.~~

~~20. The method of claim 19, wherein the E-DII epitope comprises residues 93, 104, and 106 of Yellow Fever Virus E protein.~~